The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
Investigator data shows a higher risk for suicide in patients with schizophrenia who have experienced childhood trauma with an increase in suicidal ideation linked to neglect and depression, while suicide attempts were associated with sexual abuse.
Children and adolescents undergoing infusion therapy for migraine were found to have higher levels of functional disability and a lower quality of life compared with patients not receiving infusion therapy.
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
The International Headache Society through roundtable discussion with stakeholders, such as the Clinical Trials and the Child and Adolescent Standing Committees, including lay people and pharmaceutical professionals, updated their guidelines for controlled trials of preventive treatment for migraines within the pediatric population.
The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
